HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price Target

HC Wainwright & Co. analyst Ananda Ghosh has reiterated a Buy rating on Maze Therapeutics (NASDAQ: MAZE) and maintained a price target of $110 for the stock.